Open in Screener

SGMO

Sangamo Therapeutics Inc

Feb 24 • 03:47PM ET

0.4746

+0.0829 21.18 %

Healthcare • Biotechnology • USA • NASD

Today, 2:01 PMFDA's proposed accelerated approval pathway for rare disease gene therapies drove the surge.

Peers: GILD CRSP NTLA BMRN EDIT QURE BLUE KYNB VYGR VXRT

| Held by: VTI VXF SCHA PRFZ ITOT SCHB GNOM QQQS XDNA BTEC

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	2.15%	Shs Outstand	371.69M	Perf Week	28.28%
Market Cap	176.42M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	363.69M	Perf Month	25.11%
Enterprise Value	171.31M	PEG	-	EPS next Q	0.01	Inst Own	16.83%	Short Float	6.77%	Perf Quarter	23.29%
Income	-108.91M	P/S	5.37	EPS this Y	36.89%	Inst Trans	-0.18%	Short Ratio	3.98	Perf Half Y	-19.04%
Sales	32.88M	P/B	24.48	EPS next Y	21.03%	ROA	-108.96%	Short Interest	24.62M	Perf YTD	13.01%
Book/sh	0.02	P/C	5.78	EPS next 5Y	73.79%	ROE	-480.02%	52W High	1.08 -56.05%	Perf Year	-52.54%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	26.70% 10.57%	ROIC	-343.92%	52W Low	0.34 37.58%	Perf 3Y	-82.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.48% -10.81%	Gross Margin	76.11%	Volatility	7.22% 11.42%	Perf 5Y	-96.21%
Dividend TTM	-	EV/Sales	5.21	EPS Y/Y TTM	40.47%	Oper. Margin	-335.55%	ATR (14)	0.04	Perf 10Y	-91.01%
Dividend Ex-Date	-	Quick Ratio	0.88	Sales Y/Y TTM	-37.13%	Profit Margin	-331.28%	RSI (14)	60.13	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.88	EPS Q/Q	-362.10%	SMA20	16.14%	Beta	1.36	Target Price	3.81
Payout	-	Debt/Eq	4.07	Sales Q/Q	-98.82%	SMA50	12.79%	Rel Volume	2.05	Prev Close	0.39
Employees	183	LT Debt/Eq	4.07	Earnings	Nov 06 BMO	SMA200	-6.70%	Avg Volume	6.19M	Price	0.47
IPO	Apr 06, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21900.00% -98.31%	Trades		Volume	12,304,790	Change	21.18%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-25	Downgrade	Barclays	Overweight → Equal Weight	$1
Dec-13-24	Upgrade	Truist	Hold → Buy	$7
Dec-10-24	Reiterated	H.C. Wainwright	Buy	$10
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6 → $2
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform	$5 → $1.50
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform	$16
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $5
Jun-13-22	Resumed	Wedbush	Neutral	$5
May-04-21	Initiated	RBC Capital Mkts	Outperform	$22
Jan-07-21	Resumed	Guggenheim	Neutral	$16
Jan-06-21	Initiated	Stifel	Hold	$16
Dec-16-20	Resumed	H.C. Wainwright	Buy	$25
Sep-08-20	Initiated	BofA Securities	Buy	$20
Jul-07-20	Initiated	SunTrust	Buy	$22
Aug-26-19	Initiated	H.C. Wainwright	Buy	$16
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy	$24
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight

Show Previous Ratings

Feb-03-26 04:05PM	Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026 (GlobeNewswire) -31.33% -7.64%
09:10AM	Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering (GlobeNewswire)
Jan-12-26 04:23AM	Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update (Insider Monkey)
Dec-18-25 08:05AM	Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease (GlobeNewswire)
Dec-02-25 08:05AM	Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy (GlobeNewswire)
08:05AM	Loading…
Nov-21-25 08:05AM	Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease (GlobeNewswire) +9.97%
Nov-06-25 09:15AM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -16.29%
08:17AM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
08:01AM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-30-25 04:01PM	Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call (GlobeNewswire)
Sep-04-25 08:05AM	Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 (GlobeNewswire)
Aug-14-25 12:00PM	What Makes Sangamo (SGMO) a New Buy Stock (Zacks)
Aug-07-25 05:40PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.93% -5.33%
04:41PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results (GlobeNewswire)
04:05PM	Loading…
Jul-31-25 04:05PM	Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call (GlobeNewswire)
08:40AM	Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-03-25 09:18AM	H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data (Insider Monkey)
Jun-24-25 08:05AM	Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease (Business Wire) +18.94%
May-13-25 01:01PM	Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com) -38.40%
12:14PM	Q1 2025 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 06:26PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results (Business Wire) +6.66%
06:23PM	Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering (Business Wire)
05:55PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:53PM	Sangamo: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day (Business Wire)
May-08-25 09:15AM	Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates (Zacks) +10.67%
May-06-25 04:35PM	Sangamo Therapeutics Announces First Quarter 2025 Earnings Call (Business Wire) -15.00% +6.27%
08:30AM	Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease (Business Wire)
May-05-25 10:00AM	Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
10:01AM	Loading…
May-01-25 10:01AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 04:31PM	Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) -5.93%
Apr-04-25 02:57PM	Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (Seeking Alpha) +5.50%
Apr-03-25 04:01PM	Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System (Business Wire)
Mar-18-25 09:00AM	Q4 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -16.23%
03:01AM	Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-17-25 05:10PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Sangamo: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-06-25 04:05PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference (Business Wire) +14.30%
Feb-06-25 08:05AM	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile (Business Wire)
Jan-07-25 11:32AM	Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 (Insider Monkey)
Jan-02-25 07:03AM	Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership (Barrons.com) +10.78%
Dec-31-24 11:52AM	Top Stock Movers Now: Moderna, Verisign, Dave, and More (Investopedia) -56.41%
11:18AM	Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future (GuruFocus.com)
10:34AM	Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact (Investopedia)
10:23AM	SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse (Insider Monkey)
09:56AM	Sangamo stock plummets 50% after Pfizer ends gene therapy deal (Yahoo Finance Video)
09:55AM	Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug (Bloomberg)
09:14AM	Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact (Benzinga)
08:30AM	Sangamos stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership (Pharmaceutical Technology)
06:38AM	Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal (Investing.com)
Dec-30-24 04:15PM	Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizers Decision to Cease Development of Giroctocogene Fitelparvovec (Business Wire) -8.59%
02:56PM	Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-20-24 04:37AM	Astellas and Sangamo sign capsid deal for neurological diseases (Pharmaceutical Technology) +6.93%
Dec-19-24 02:30AM	Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases (Business Wire)
02:30AM	Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases (PR Newswire)
Nov-19-24 04:15PM	Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain (Business Wire)
Nov-13-24 09:49AM	Q3 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -9.96%
02:16AM	Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 05:15PM	Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:09PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (Business Wire)
Nov-04-24 04:15PM	Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast (Business Wire) -7.45% +24.14%
Oct-23-24 07:45AM	Merck acquires cancer drug startup; Elevidys ex-US sales rise (BioPharma Dive) +27.27%
Oct-22-24 08:05AM	Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 (Business Wire) +32.53%
Aug-07-24 01:24PM	Q2 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.46%
04:32AM	Genentech and Sangamo to develop neurodegenerative disease therapies (Pharmaceutical Technology)
Aug-06-24 05:35PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +28.95%
04:37PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results (Business Wire)
08:11AM	Roche licenses Sangamos technology for another shot at Alzheimers drugs (BioPharma Dive)
08:05AM	Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases (Business Wire)
Jul-30-24 04:15PM	Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast (Business Wire) -23.64% +11.80%
Jul-24-24 06:55AM	Sangamo Therapeutics Reports on Pfizers Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate (Business Wire) +39.55%
May-12-24 08:28AM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:58PM	Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights (GuruFocus.com) +7.26%
May-09-24 08:58PM	SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:25PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Sangamo: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results (Business Wire)
10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:05AM	Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing (Business Wire)
May-02-24 04:15PM	Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast (Business Wire) +6.48%
Apr-22-24 04:35PM	Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire)
Mar-22-24 08:05AM	Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering (Business Wire) -27.55%
Mar-14-24 07:23AM	Q4 2023 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:21AM	Sangamo: Q4 Earnings Snapshot (Associated Press Finance) -8.83%
08:05AM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
08:01AM	Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs (Business Wire)
Mar-12-24 06:30PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast (Business Wire)
Feb-12-24 08:05AM	Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease (Business Wire) +40.15%
Feb-05-24 06:01PM	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile (Business Wire) +13.91% -7.02%
Nov-03-23 05:03PM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:15AM	Sangamo to cut jobs again with planned business overhaul (BioPharma Dive) -22.14%
Nov-01-23 07:05PM	Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update (GuruFocus.com) -6.25%
04:13PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 10:02AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-23 04:15PM	Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (Business Wire)

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Open in Screener

VSTM

Verastem Inc

Feb 24 • 03:47PM ET

5.89

+0.19 3.25 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD AMGN MRK PFE BMY REGN VRTX INCY LUMO SRPT

| Held by: VTI XBI IWM VXF FESM VTWO IWO IWN IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-4.26	Insider Own	16.08%	Shs Outstand	66.75M	Perf Week	0.43%
Market Cap	443.28M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	-0.60%	Shs Float	64.58M	Perf Month	-7.75%
Enterprise Value	395.05M	PEG	-	EPS next Q	-0.52	Inst Own	91.84%	Short Float	25.49%	Perf Quarter	-40.01%
Income	-241.10M	P/S	33.13	EPS this Y	14.84%	Inst Trans	20.84%	Short Ratio	8.59	Perf Half Y	-35.18%
Sales	13.38M	P/B	-	EPS next Y	46.30%	ROA	-159.02%	Short Interest	16.46M	Perf YTD	-23.77%
Book/sh	-0.23	P/C	3.22	EPS next 5Y	36.78%	ROE	-2888.70%	52W High	11.24 -47.66%	Perf Year	5.85%
Cash/sh	1.83	P/FCF	-	EPS past 3/5Y	9.28% 31.36%	ROIC	-350.20%	52W Low	4.01 46.77%	Perf 3Y	9.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	154.59% -10.54%	Gross Margin	80.93%	Volatility	5.18% 6.30%	Perf 5Y	-80.92%
Dividend TTM	-	EV/Sales	29.53	EPS Y/Y TTM	-26.37%	Oper. Margin	-1197.72%	ATR (14)	0.41	Perf 10Y	-56.98%
Dividend Ex-Date	-	Quick Ratio	2.55	Sales Y/Y TTM	33.79%	Profit Margin	-1802.12%	RSI (14)	41.33	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.58	EPS Q/Q	-126.22%	SMA20	-4.68%	Beta	0.40	Target Price	17.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-15.84%	Rel Volume	0.38	Prev Close	5.70
Employees	78	LT Debt/Eq	-	Earnings	Mar 04 BMO	SMA200	-22.08%	Avg Volume	1.92M	Price	5.89
IPO	Jan 27, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-118.91% 95.30%	Trades		Volume	706,631	Change	3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-26	Initiated	H.C. Wainwright	Buy	$18
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy	$15
Mar-24-25	Reiterated	H.C. Wainwright	Buy	$7 → $10
Dec-31-24	Reiterated	BTIG Research	Buy	$13 → $20
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15

Show Previous Ratings

Feb-18-26 07:30AM	Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
Feb-17-26 12:00PM	What Makes Verastem (VSTM) a New Buy Stock (Zacks)
Feb-16-26 01:02AM	Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts (MarketBeat)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.51%
Feb-04-26 08:00AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.) +7.78%
07:30AM	Loading…
07:30AM	Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
Jan-12-26 04:01PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.73%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +11.05%
Dec-29-25 04:01PM	Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire)
Dec-15-25 04:01PM	Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth (Business Wire) -6.80%
Nov-25-25 07:30AM	Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks) -6.84%
12:41AM	Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Nov-13-25 04:07PM	Verastem Oncology Announces Proposed Public Offering of Common Stock (Business Wire)
07:30AM	Loading…
Nov-05-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-25 04:02PM	Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... (GuruFocus.com) -20.10%
08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:40AM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-03-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's Why (Zacks)
Oct-29-25 11:57AM	Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment (Insider Monkey)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-23-25 04:01PM	Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors (Business Wire)
09:55AM	Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
07:30AM	Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-21-25 10:00AM	Best Momentum Stocks to Buy for Oct. 21 (Zacks)
06:39AM	New Strong Buy Stocks for Oct. 21: NEM, AS and More (Zacks)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice (Zacks) -13.02%
09:55AM	Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet (Zacks)
04:15AM	Loading…
Oct-19-25 04:15AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.14%
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -7.03%
Aug-27-25 07:00AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Aug-17-25 03:22AM	Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects (Insider Monkey)
Aug-13-25 04:29PM	Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer (Business Wire)
Aug-07-25 06:40PM	Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +19.93%
05:36PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-29-25 07:30AM	Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-24-25 07:30AM	Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Business Wire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-14-25 07:42AM	Verastems avutometinib combination shows 31% ORR in ovarian cancer trial (Clinical Trials Arena) +5.87%
Jul-11-25 04:12PM	Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology (Business Wire)
Jul-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:02PM	Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer (Business Wire)
Jun-24-25 04:02PM	Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors (Business Wire) -5.70%
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks) -5.01%
Jun-02-25 09:40AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor (Business Wire) -19.95%
May-28-25 10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks) -10.68%
07:30AM	Verastem Oncology to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-25 05:15PM	Verastem announces positive Phase 1/2 safety and efficacy results in PDAC (TipRanks) +11.10%
May-22-25 05:01PM	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma (Business Wire)
May-20-25 11:39AM	Tempus partners with Verastem for companion diagnostic development (Medical Device Network)
08:30AM	Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment (Business Wire)
May-13-25 04:50PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:34PM	Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
May-09-25 11:55AM	FDA grants accelerated approval to avutometinib, defactinib combination (TipRanks)
May-08-25 02:47PM	FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer (Benzinga)
01:17PM	FDA Approves the AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
May-01-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Apr-25-25 09:00AM	Verastem Oncology Announces $75 million Private Placement (Business Wire)
Apr-23-25 04:05PM	Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors (Business Wire) +5.34%
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks) +13.37%
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-10-25 02:35PM	Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (Seeking Alpha) -14.39%
Apr-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:55AM	Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade (Zacks) +5.16%
Mar-25-25 04:35PM	Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 05:15PM	Verastem files to sell 1.42M shares of common stock by selling shareholders (SeekingAlpha)
04:17PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-20-25 04:05PM	Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer (Business Wire)
Jan-29-25 07:30AM	Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference (Business Wire)
Jan-23-25 07:30AM	Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-15-25 07:30AM	Verastem Oncology Names Matthew E. Ros as Chief Operating Officer (Business Wire) +5.36%
Jan-14-25 07:30AM	Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China (Business Wire) -5.62%
Jan-13-25 07:30AM	Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 (Business Wire) -6.81%
Jan-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.79%
Dec-31-24 10:33AM	Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application (GuruFocus.com) +40.87%
Dec-30-24 04:30PM	Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-20-24 07:00AM	Applied Therapeutics Appoints John H. Johnson as Executive Chairman (GlobeNewswire) -5.63%
Dec-18-24 07:30AM	Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire) -7.39%
Nov-26-24 07:00AM	Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-06-24 05:00PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -6.98%
04:05PM	Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-01-24 12:02PM	Verastem Oncology submits NDA for ovarian cancer treatment (Pharmaceutical Technology)
Oct-31-24 04:01PM	Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
07:30AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Oct-17-24 01:00AM	Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting (Business Wire) -20.12%
Oct-09-24 06:00AM	Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting (Business Wire)
Oct-07-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-10-24 04:05PM	Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference (Business Wire) +8.76%
07:30AM	Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting (Business Wire)
Sep-03-24 07:30AM	Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 (Business Wire)
Aug-08-24 06:18PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paterson Dan	President and CEO	Feb 04 '26	Sale	6.69	970	6,489	612,919	Feb 05 04:10 PM
Dan Paterson	Officer	Jan 12 '26	Proposed Sale	7.16	5,039	36,069		Jan 14 05:15 PM
Dan Paterson	Officer, Director	Jan 12 '26	Proposed Sale	7.16	10,321	73,851		Jan 14 05:13 PM
Paterson Dan	President and CEO	Jan 12 '26	Sale	7.16	10,321	73,898	400,104	Jan 14 05:12 PM
Calkins Daniel	Chief Financial Officer	Jan 12 '26	Sale	7.16	5,039	36,079	104,719	Jan 14 05:11 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '25	Sale	7.86	80	629	109,758	Dec 29 12:24 PM
Stuglik Brian M	Director	Dec 16 '25	Sale	9.14	592	5,411	101,147	Dec 18 04:47 PM
Paterson Dan	President and CEO	Dec 16 '25	Sale	9.14	393	3,592	410,425	Dec 18 04:46 PM
Gagnon Robert E.	Director	Dec 16 '25	Sale	9.14	283	2,587	41,678	Dec 18 04:45 PM
Paterson Dan	President and CEO	Dec 10 '25	Sale	10.07	2,000	20,140	412,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 11 '25	Sale	10.00	2,000	20,000	410,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 05 '25	Sale	10.61	2,000	21,220	418,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 08 '25	Sale	10.50	2,000	21,000	416,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 09 '25	Sale	10.25	2,000	20,500	414,818	Dec 09 05:03 PM
Paterson Dan	Officer	Dec 09 '25	Proposed Sale	10.27	7,790	80,003		Dec 09 03:11 PM
Paterson Dan	President and CEO	Dec 02 '25	Sale	10.32	2,000	20,640	424,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 04 '25	Sale	10.00	2,000	20,000	420,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 03 '25	Sale	10.00	2,000	20,000	422,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Nov 28 '25	Sale	10.79	2,000	21,580	428,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Dec 01 '25	Sale	10.39	2,000	20,780	426,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Nov 26 '25	Sale	10.32	2,000	20,640	430,818	Dec 01 04:40 PM
Bunn Paul A.	Director	Nov 21 '25	Option Exercise	3.27	6,250	20,438	8,333	Nov 25 05:35 PM
Bunn Paul A.	Director	Nov 21 '25	Sale	10.00	6,250	62,500	2,083	Nov 25 05:35 PM
Kauffman Michael	Director	Nov 21 '25	Sale	10.00	8,550	85,500	8,666	Nov 25 05:34 PM
Paterson Dan	President and CEO	Nov 25 '25	Sale	10.00	2,000	20,000	432,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 24 '25	Sale	10.00	2,000	20,000	434,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 21 '25	Sale	10.00	2,000	20,000	436,818	Nov 25 05:32 PM
Kauffman Michael	Board Member	Nov 21 '25	Proposed Sale	9.81	8,550	83,876		Nov 21 04:20 PM
Bunn Paul A.	Board Member	Nov 21 '25	Proposed Sale	9.81	6,250	61,312		Nov 21 04:10 PM
Paterson Dan	President and CEO	Nov 03 '25	Sale	9.74	3,299	32,146	438,818	Nov 06 12:21 PM
Bunn Paul A.	Director	Oct 09 '25	Sale	9.06	8,333	75,497	8,333	Oct 14 04:31 PM
Bunn Paul A.	Board Member	Oct 09 '25	Proposed Sale	8.94	8,333	74,497		Oct 09 04:05 PM
Calkins Daniel	Chief Financial Officer	Sep 22 '25	Sale	9.08	57	518	109,863	Sep 24 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 24 '25	Sale	9.23	25	231	109,838	Sep 24 04:30 PM
Stuglik Brian M	Director	Sep 16 '25	Sale	9.99	587	5,864	101,739	Sep 18 06:16 PM
Gagnon Robert E.	Director	Sep 16 '25	Sale	9.99	281	2,807	41,961	Sep 18 06:14 PM
Paterson Dan	President and CEO	Sep 16 '25	Sale	9.99	390	3,896	442,117	Sep 18 06:11 PM
Paterson Dan	Officer	Sep 17 '25	Proposed Sale	9.76	31,790	310,429		Sep 04 12:39 PM
Paterson Dan	President and CEO	Aug 06 '25	Sale	5.81	1,332	7,739	442,507	Aug 06 08:38 PM
Paterson Dan	President and CEO	Jun 20 '25	Sale	5.13	17,808	91,355	443,839	Jun 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '25	Sale	5.13	4,110	21,084	109,945	Jun 24 04:37 PM
Calkins Daniel	Chief Financial Officer	Jun 23 '25	Sale	4.71	25	118	109,920	Jun 24 04:37 PM
Dan Paterson	Officer	Jun 20 '25	Proposed Sale	5.13	17,808	91,334		Jun 20 05:35 PM
Paterson Dan	President and CEO	Jun 16 '25	Sale	5.65	335	1,893	461,647	Jun 20 11:22 AM
Gagnon Robert E.	Director	Jun 16 '25	Sale	5.65	284	1,605	42,242	Jun 20 11:22 AM
Stuglik Brian M	Director	Jun 16 '25	Sale	5.65	594	3,356	102,326	Jun 20 11:21 AM
Calkins Daniel	Chief Financial Officer	May 20 '25	Sale	8.13	11,143	90,593	114,055	May 20 07:54 PM
Paterson Dan	President and CEO	May 20 '25	Sale	8.13	58,677	477,044	461,982	May 20 07:52 PM
Daniel Calkins	Officer	May 20 '25	Proposed Sale	8.10	11,143	90,293		May 20 07:49 PM
Dan Paterson	Officer, Director	May 20 '25	Proposed Sale	8.13	58,677	477,044		May 20 07:48 PM
Paterson Dan	President and CEO	May 05 '25	Sale	7.30	820	5,986	345,659	May 07 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '25	Sale	6.89	65	448	86,374	Mar 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Mar 24 '25	Sale	7.04	26	183	86,348	Mar 24 04:39 PM
Paterson Dan	President and CEO	Mar 17 '25	Sale	6.95	244	1,696	346,479	Mar 19 04:48 PM
Gagnon Robert E.	Director	Mar 17 '25	Sale	6.95	284	1,974	34,193	Mar 19 04:47 PM
Stuglik Brian M	Director	Mar 17 '25	Sale	6.95	593	4,121	94,587	Mar 19 04:46 PM

Open in Screener

XXII

22nd Century Group Inc

Feb 24 • 03:45PM ET

4.74

-0.06 -1.25 %

Consumer Defensive • Tobacco • USA • NASD

XXII 22nd Century Group Inc daily Stock Chart

Peers: PM MO BTI UVV RLX TPB GNLN CIG CNTY GRWG

Index	-	P/E	-	EPS (ttm)	-7212.64	Insider Own	3.31%	Shs Outstand	0.51M	Perf Week	-17.99%
Market Cap	2.42M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	0.00%	Shs Float	0.49M	Perf Month	-54.88%
Enterprise Value	1.48M	PEG	-	EPS next Q	-2.10	Inst Own	11.56%	Short Float	5.90%	Perf Quarter	-60.56%
Income	-9.39M	P/S	0.13	EPS this Y	99.98%	Inst Trans	-	Short Ratio	1.31	Perf Half Y	-83.96%
Sales	18.07M	P/B	0.12	EPS next Y	90.00%	ROA	-49.81%	Short Interest	0.03M	Perf YTD	-58.96%
Book/sh	39.44	P/C	0.50	EPS next 5Y	-	ROE	-133.50%	52W High	1093.65 -99.57%	Perf Year	-99.48%
Cash/sh	9.50	P/FCF	-	EPS past 3/5Y	70.48% 52.01%	ROIC	-43.19%	52W Low	4.80 -1.25%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-7.64% -1.15%	Gross Margin	-22.01%	Volatility	14.39% 12.95%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	0.08	EPS Y/Y TTM	99.30%	Oper. Margin	-69.66%	ATR (14)	0.83	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.90	Sales Y/Y TTM	-34.81%	Profit Margin	-51.98%	RSI (14)	28.58	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.17	EPS Q/Q	100.03%	SMA20	-24.83%	Beta	1.03	Target Price	135.00
Payout	-	Debt/Eq	0.21	Sales Q/Q	-32.54%	SMA50	-54.88%	Rel Volume	1.78	Prev Close	4.80
Employees	56	LT Debt/Eq	0.18	Earnings	Nov 04 BMO	SMA200	-93.05%	Avg Volume	22.17K	Price	4.74
IPO	Jan 26, 2011	Option/Short	No / Yes	EPS/Sales Surpr.	93.69% -4.50%	Trades		Volume	37,968	Change	-1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-22	Initiated	Alliance Global Partners	Buy	$5
Jun-15-22	Initiated	Craig Hallum	Buy	$5
Mar-08-22	Initiated	ROTH Capital	Buy	$6
Jul-23-21	Initiated	Cowen	Outperform	$5
Oct-16-17	Reiterated	Chardan Capital Markets	Buy	$3.50 → $11.50
Aug-11-16	Reiterated	Chardan Capital Markets	Buy	$4.50 → $3.50

Feb-23-26 05:07PM	22nd Century Group Reports Continued Early Sales Momentum for VLN Cigarette Products (GlobeNewswire) -15.64%
Feb-20-26 04:15PM	22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) -8.52%
Jan-15-26 09:00AM	22nd Century CEO & Chairman Larry Firestone Provides 2025 Year-in-Review Letter to Stockholders (GlobeNewswire)
Jan-12-26 04:30PM	22nd Century to Participate in the Needham Annual Growth Conference January 16, 2026 (GlobeNewswire) -6.04%
Jan-06-26 06:10AM	22nd Century Files VLN MRTP Renewal - Only Combustible Tobacco Product Authorized by the FDA Specifically to Help Smokers Smoke Less (GlobeNewswire)
09:29AM	Loading…
Dec-09-25 09:29AM	22nd Century to Participate in the Emerging Growth Conference on December 10, 2025 (GlobeNewswire)
Nov-26-25 10:21AM	Emerging Growth Research Releases Q3 2025 Update Report on 22nd Century Group (Newsfile) +20.31%
Nov-05-25 12:13AM	22nd Century Group Inc (XXII) Q3 2025 Earnings Call Highlights: Strategic Shifts and Financial ... (GuruFocus.com)
Nov-04-25 06:24AM	22nd Century: Q3 Earnings Snapshot (Associated Press Finance) -16.77%
06:00AM	22nd Century Group Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-28-25 05:07PM	22nd Century Announces Receipt of $9.5 Million from Settlement of Insurance Claim (GlobeNewswire) +6.62%
Oct-23-25 07:45AM	22nd Century Launches VLN with Major C-Store Chain, New Marketing Collateral, Continues to Expand State Authorizations (GlobeNewswire)
Oct-21-25 08:00AM	22nd Century Group to Announce Third Quarter 2025 Results on November 4, 2025 (GlobeNewswire)
Sep-30-25 09:05AM	22nd Century Submits Comments to FDA in Support of Proposed Reduced Nicotine Content Mandate (GlobeNewswire)
Sep-24-25 04:45PM	22nd Century Secures $9.5 Million Cash Proceeds from Settlement of Insurance Claim (GlobeNewswire) +31.13%
04:15PM	Loading…
Sep-18-25 04:15PM	22nd Century Announces Debt-Free Balance Sheet and New Growth Capital (GlobeNewswire) +11.93%
Sep-08-25 09:39AM	Two 'Red Flags' You Need To Watch When Investing In Bitcoin Treasury Firms (Benzinga) -5.26%
Sep-05-25 05:37PM	22nd Century to Participate in the HC Wainwright Conference in New York City September 9, 2025 (GlobeNewswire)
Aug-22-25 03:17PM	Emerging Growth Research Releases Q2 2025 Update Report on 22nd Century Group (Newsfile)
Aug-20-25 07:00AM	22nd Century CEO & Chairman Larry Firestone Provides Technology and Regulatory Update Letter to Stockholders (GlobeNewswire)
Aug-18-25 08:36AM	22nd Century to Participate in the Emerging Growth Conference on August 20, 2025 (GlobeNewswire)
Aug-14-25 06:30AM	22nd Century: Q2 Earnings Snapshot (Associated Press Finance) -10.11%
06:00AM	22nd Century Group Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-07-25 08:30AM	22nd Century Group to Announce Second Quarter 2025 Results on August 14, 2025 (GlobeNewswire)
Aug-04-25 08:00AM	22nd Century Announces First Shipments of Pinnacle VLN Products to Top 5 C-Store Chain Locations Across 12 States (GlobeNewswire)
Jul-29-25 05:00PM	22nd Century Applauds the American Academy of Family Physicians Comments and Support of the FDA's Proposed Reduced Nicotine Mandate to Reduce Smoking, Transform Public Health, Save Lives and Reduce Health Costs (GlobeNewswire) -8.41%
Jul-17-25 05:00PM	22nd Century Reports Expanded State Authorization Progress to Sell VLN, Partner VLN and Conventional Products (GlobeNewswire) +6.99% -20.20%
Jul-16-25 05:18PM	VLN Commercial Launches Confirm Viability of the FDA's Proposed Reduced Nicotine Mandate (GlobeNewswire)
Jul-10-25 08:00AM	22nd Century Provides Corporate Update On Its VLN MRTP Renewal Process - The First and Only Combustible Tobacco Product Authorized by the FDA Specifically to Help Smokers Smoke Less (GlobeNewswire) +11.11%
Jun-26-25 08:00AM	22nd Century Announces Operation 100 - A 100mm VLN Cigarette Designed to Reach Even More Adult Smokers Who Want to Reduce Their Nicotine Consumption (GlobeNewswire) +20.75%
09:00AM	Loading…
Jun-24-25 09:00AM	22nd Century Announces Second Partner VLN Product Deal as Part of Major Pinnacle Brand Expansion Agreement with Top-5 C-Store Chain (GlobeNewswire) -10.60%
May-21-25 09:00AM	Emerging Growth Research Releases Q1 2025 Update Report on 22nd Century Group (Newsfile)
May-20-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire) -5.45%
May-19-25 04:15PM	22nd Century to Present at the Emerging Growth Conference on May 21, 2025 (GlobeNewswire)
May-14-25 03:04AM	22nd Century Group Inc (XXII) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
May-13-25 06:00AM	22nd Century Group Reports First Quarter 2025 Financial Results (GlobeNewswire) +7.48%
May-08-25 06:15PM	Monster Beverage (MNST) Tops Q1 Earnings Estimates (Zacks) -16.00%
05:07PM	22nd Century Group Completes Sale of Needle Rock Farms Assets (GlobeNewswire)
May-07-25 08:00AM	22nd Century Group Further Reduces Debt by $1.0 Million Following Financing Transaction (GlobeNewswire) +5.04%
07:40AM	Turning Point Brands (TPB) Q1 Earnings and Revenues Top Estimates (Zacks)
May-05-25 08:00AM	22nd Century Group to Announce First Quarter 2025 Results on May 13, 2025 (GlobeNewswire) +39.30%
Apr-29-25 08:15AM	Altria (MO) Q1 Earnings Beat Estimates (Zacks)
Apr-23-25 08:15AM	Philip Morris (PM) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +9.11%
Apr-17-25 04:30PM	22nd Century Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions (GlobeNewswire)
Apr-16-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire) -8.59%
Apr-15-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire)
Apr-10-25 09:00AM	Emerging Growth Research Releases Quarterly Update Report on 22nd Century Group (XXII) (Newsfile) -10.94%
Apr-09-25 08:25AM	22nd Century Revenue Growth from Continued Expansion of CMO Volume with New Filtered Cigar Agreements (GlobeNewswire)
Apr-08-25 08:00AM	22nd Century CEO & Chairman Larry Firestone Provides Corporate Update Letter to Stockholders (GlobeNewswire)
Mar-20-25 11:01AM	22nd Century outlines plans for VLN expansion and growth in 2025 (SeekingAlpha)
11:01AM	22nd Century Group, Inc. (XXII) Q4 2024 Earnings Call Transcript (SeekingAlpha)
06:00AM	22nd Century Group Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha)
Mar-14-25 08:00AM	22nd Century Group to Announce Fourth Quarter and Full Year 2024 Results on March 20, 2025 (GlobeNewswire) -11.34%
Mar-10-25 09:00AM	22nd Century Announces First Partner VLN Agreement, New VLN Availability with Smoker Friendly (GlobeNewswire)
Feb-19-25 09:00AM	Emerging Growth Research Releases New Initiation Report on the 22nd Century Group (XXII) (Newsfile)
06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-06-25 09:00AM	22nd Century to Present at the Emerging Growth Conference on February 19, 2025 (GlobeNewswire) -7.99%
Jan-27-25 04:05PM	22nd Century Regains Full Compliance with Nasdaq Continued Listing Standards (GlobeNewswire) -6.28%
Jan-15-25 11:37AM	FDA Publishes Proposed New Tobacco Product Standard for Nicotine Yield, Citing VLN from 22nd Century as the Only Combustible Cigarette That Complies with the New Standard (GlobeNewswire) +21.57%
Jan-14-25 09:25AM	Washington Post Story Featuring 22nd Century VLN Products Highlights Proposed FDA Reduced Nicotine Content Policy Could Initially Benefit An Estimated 13 Million Smokers (GlobeNewswire) +5.83%
Jan-13-25 07:30AM	22nd Century Stands Ready to Support the Adoption of FDA Proposed Tobacco Product Standard to Mandate Reduced Nicotine Content in Cigarettes with its VLN Cigarettes (GlobeNewswire) +22.70%
Jan-07-25 08:30AM	22nd Century Group Signs New, Expanded License and Manufacturing Agreement with Smoker Friendly (GlobeNewswire)
Dec-13-24 08:45AM	22nd Century Announces 1-for-135 Reverse Stock Split (Newsfile) -33.20%
Dec-12-24 11:31AM	22nd Century Applauds FDA Proposal to Mandate Reduced Nicotine Content in Cigarettes (Newsfile)
Nov-13-24 02:05AM	22nd Century Group Inc (XXII) Q3 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
Nov-12-24 06:00AM	22nd Century Group Reports Third Quarter 2024 Financial Results (Newsfile)
Nov-07-24 11:05AM	22nd Century Group (XXII) to Announce Third Quarter 2024 Results on November 12, 2024 (Newsfile) +14.56%
Oct-21-24 09:00AM	22nd Century Group to Present at the LD Micro Main Event XVII on October 30 in Los Angeles (Newsfile)
Oct-08-24 08:00AM	22nd Century Regains Compliance with Nasdaq Stockholders' Equity Requirement (Newsfile) -5.98%
Sep-25-24 08:00AM	22nd Century Continues CMO Business Expansion with Additional Filtered Cigar Volume (Newsfile)
Sep-23-24 08:00AM	22nd Century Announces New Branded Products Order with Customer for Southeast Asia (Newsfile) +10.73%
Sep-11-24 07:55AM	22nd Century Updates Strategic Growth Initiatives for VLN (Newsfile) -13.68%
Sep-09-24 08:00AM	22nd Century Satisfies IP Licensing and Sponsored Research Obligations to NCSU Through 2025 in an Equity Transaction (Newsfile) +23.79%
Sep-06-24 11:58AM	22nd Century Group to Participate in the HC Wainwright Conference on September 10, 2024 (Newsfile)
Aug-28-24 09:10AM	22nd Century Raises $1.68 Million in Regulation A Offering, Amends Senior Secured Credit Facility (Newsfile) -15.26%
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 05:52PM	22nd Century Group to Participate in the Emerging Growth Virtual Conference on August 21, 2024 (Newsfile)
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-13-24 02:00AM	22nd Century Group Reports Second Quarter 2024 Financial Results (Newsfile)
Aug-06-24 08:00AM	22nd Century Group to Announce Second Quarter 2024 Results on August 13, 2024 (Newsfile)
Jul-30-24 04:10PM	22nd Century Appoints Robert Manfredonia as Executive Vice President of Sales and Marketing (Newsfile) -8.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-10-24 04:30AM	22nd Century Announces New Greenbutts Manufacturing Agreement for Innovative Plant-Based, Biodegradable Cigarette Filters (Newsfile) +7.83%
Jul-09-24 08:30AM	22nd Century to Re-Launch and Expand VLN(R) Presence in South Korea (Newsfile)
Jul-08-24 08:30AM	22nd Century Group to Participate in the Emerging Growth Virtual Conference on July 17, 2024 (Newsfile)
Jun-25-24 05:00PM	22nd Century Reduces Debt by Additional $1.5 Million via Payment from GVB (Newsfile) +6.27% +5.00%
May-30-24 12:05PM	22nd Century Announces Resignation of John Miller as President of Tobacco (Newsfile) -12.20%
May-15-24 10:52AM	XXII Stock Earnings: 22nd Century Group Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:00AM	22nd Century Group Reports First Quarter 2024 Financial Results (Newsfile)
May-13-24 08:00AM	22nd Century Eliminates an Additional $2.3 Million of Debt (Newsfile)
May-08-24 09:18AM	22nd Century Group to Participate in the Aegis Capital Virtual Conference on May 9, 2024 (Newsfile)
May-07-24 08:15AM	22nd Century Group (XXII) to Announce First Quarter 2024 Results on May 15, 2024 (Newsfile)
Apr-30-24 09:00AM	22nd Century Eliminates $5.2 Million of Debt in Above-Market Equity Transaction (Newsfile) -5.95%
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-18-24 05:00PM	22nd Century Group Announces Resignation of Sullivan and Mish from the Board of Directors (Newsfile) -5.26%
09:00AM	22nd Century Group Regains Compliance with NASDAQ Minimum Bid Price Rule (Newsfile)
Apr-15-24 09:00AM	22nd Century Group to Participate in the Planet MicroCap Showcase on May 1-2, 2024 (Newsfile)
Apr-11-24 04:45PM	22nd Century Group Expands CMO Business with New Pinnacle Brand Cigarillo Products (Newsfile)

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Mocksville, NC.

SGMO

Sangamo Therapeutics Inc

VSTM

Verastem Inc

XXII

22nd Century Group Inc

Upgrade your FINVIZ experience